IBRX
Price
$2.52
Change
-$0.15 (-5.60%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
2.37B
74 days until earnings call
QTTB
Price
$1.63
Change
-$0.03 (-1.81%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
20.13M
Interact to see
Advertisement

IBRX vs QTTB

Header iconIBRX vs QTTB Comparison
Open Charts IBRX vs QTTBBanner chart's image
ImmunityBio
Price$2.52
Change-$0.15 (-5.60%)
Volume$96.67K
Capitalization2.37B
Q32 Bio
Price$1.63
Change-$0.03 (-1.81%)
Volume$1.06K
Capitalization20.13M
IBRX vs QTTB Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBRX vs. QTTB commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and QTTB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (IBRX: $2.68 vs. QTTB: $1.66)
Brand notoriety: IBRX and QTTB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 95% vs. QTTB: 0%
Market capitalization -- IBRX: $2.37B vs. QTTB: $20.13M
IBRX [@Biotechnology] is valued at $2.37B. QTTB’s [@Biotechnology] market capitalization is $20.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 1 FA rating(s) are green whileQTTB’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 1 green, 4 red.
  • QTTB’s FA Score: 0 green, 5 red.
According to our system of comparison, IBRX is a better buy in the long-term than QTTB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 6 TA indicator(s) are bullish while QTTB’s TA Score has 3 bullish TA indicator(s).

  • IBRX’s TA Score: 6 bullish, 3 bearish.
  • QTTB’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, IBRX is a better buy in the short-term than QTTB.

Price Growth

IBRX (@Biotechnology) experienced а +0.37% price change this week, while QTTB (@Biotechnology) price change was -4.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

IBRX is expected to report earnings on Aug 06, 2025.

QTTB is expected to report earnings on Mar 11, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.37B) has a higher market cap than QTTB($20.1M). IBRX YTD gains are higher at: 4.688 vs. QTTB (-51.744). QTTB has higher annual earnings (EBITDA): -44.5M vs. IBRX (-264.43M). IBRX has more cash in the bank: 150M vs. QTTB (78M). QTTB has less debt than IBRX: QTTB (18.9M) vs IBRX (504M). IBRX has higher revenues than QTTB: IBRX (14.7M) vs QTTB (0).
IBRXQTTBIBRX / QTTB
Capitalization2.37B20.1M11,766%
EBITDA-264.43M-44.5M594%
Gain YTD4.688-51.744-9%
P/E RatioN/AN/A-
Revenue14.7M0-
Total Cash150M78M192%
Total Debt504M18.9M2,667%
FUNDAMENTALS RATINGS
IBRX vs QTTB: Fundamental Ratings
IBRX
QTTB
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6595
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for QTTB (48) in the null industry. This means that IBRX’s stock grew somewhat faster than QTTB’s over the last 12 months.

IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that IBRX’s stock grew similarly to QTTB’s over the last 12 months.

IBRX's SMR Rating (100) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that IBRX’s stock grew similarly to QTTB’s over the last 12 months.

IBRX's Price Growth Rating (65) in the Biotechnology industry is in the same range as QTTB (95) in the null industry. This means that IBRX’s stock grew similarly to QTTB’s over the last 12 months.

IBRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that IBRX’s stock grew similarly to QTTB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXQTTB
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LHCVX17.81N/A
N/A
Lord Abbett Health Care R6
VYMRX15.89N/A
N/A
Voya Mid Cap Research Enhanced Index C
LGOAX35.76N/A
N/A
Patient Opportunity A
PRPZX6.19N/A
N/A
PGIM Jennison Energy Infrastructure Z
HGOFX64.40N/A
N/A
Hartford Growth Opportunities F

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
+1.13%
AXON - IBRX
48%
Loosely correlated
N/A
CLRB - IBRX
42%
Loosely correlated
N/A
ARRY - IBRX
41%
Loosely correlated
N/A
RXRX - IBRX
39%
Loosely correlated
N/A
QTTB - IBRX
37%
Loosely correlated
N/A
More

QTTB and

Correlation & Price change

A.I.dvisor indicates that over the last year, QTTB has been closely correlated with CLRB. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if QTTB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QTTB
1D Price
Change %
QTTB100%
N/A
CLRB - QTTB
76%
Closely correlated
N/A
MESO - QTTB
51%
Loosely correlated
-3.82%
STOK - QTTB
49%
Loosely correlated
N/A
ADCT - QTTB
47%
Loosely correlated
+13.20%
ANAB - QTTB
43%
Loosely correlated
N/A
More